{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:41Z","timestamp":1784696801402,"version":"3.55.0"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Triple-negative breast cancer (TNBC) accounts for approximately 15\u201320% of all breast cancers and is characterized by the absence of hormone receptors and\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification. Early-stage TNBC is characterized by aggressive clinical behavior, high proliferative rates, early relapses, and a propensity for visceral metastases resulting in poor long-term outcomes despite initial chemosensitivity. The introduction of neoadjuvant chemo-immunotherapy, combining standard chemotherapy with immune checkpoint inhibitors (ICIs), has significantly improved pathological complete response (pCR) rates and has reshaped treatment paradigms in early TNBC. Despite these advances, a substantial proportion of patients still develop residual disease or relapse, underscoring the need for better biomarkers to guide treatment decisions. This review provides a comprehensive overview of current and emerging biomarkers in TNBC, focusing on their role in the era of neoadjuvant chemo-immunotherapy. Established clinical markers, such as pCR and residual cancer burden (RCB), remain essential for post-neoadjuvant risk stratification. Beyond these, emerging biomarkers, including tumor-infiltrating lymphocytes (TILs), programmed death ligand 1 (PD-L1), spatial immune profiling, circulating tumor DNA (ctDNA), microRNAs (miRNAs), and oncogenic signaling pathways (e.g., PI3K\/AKT, MAPK, WNT\/\u03b2-catenin), are under investigation for their potential to refine patient selection and predict response or resistance to therapy. The biological heterogeneity of TNBC, encompassing both tumor-intrinsic and immune microenvironment variations, contributes to differential treatment outcomes and complicates clinical decision-making. We discuss the challenges of integrating emerging biomarkers into routine clinical practice, including standardization, prospective validation, and development of combined predictive models. By summarizing both current and investigational biomarkers, this review aims to support clinicians in understanding how biomarker-driven strategies may optimize neoadjuvant therapy, reduce unnecessary toxicity, and ultimately improve long-term outcomes in TNBC.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1842762","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:49:20Z","timestamp":1784695760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Mariarosaria","family":"D\u2019Amato","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Morritti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]},{"name":"Breast Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Morelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ciuffreda","sequence":"additional","affiliation":[{"name":"Breast Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Castelvetere","sequence":"additional","affiliation":[{"name":"Breast Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]},{"name":"Anatomo Pathology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Pia","family":"Mangiacotti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pasculli","sequence":"additional","affiliation":[{"name":"Translational Medicine Department, Breast and Ovarian Cancer Research Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parrella","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]},{"name":"Translational Medicine Department, Breast and Ovarian Cancer Research Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, FG, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer \u2013 expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.003","article-title":"Residual disease post- neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment","volume":"35","author":"Agostinetto","year":"2024","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3690","article-title":"Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial","volume":"7","author":"Symmans","year":"2021","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32772-7","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s12672-025-03435-w","article-title":"Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis","volume":"16","author":"Du","year":"2025","journal-title":"Discov Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0053","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 5.2025","volume":"23","author":"Gradishar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052559","article-title":"Unraveling biomarker signatures in triple-negative breast cancer: a systematic review for targeted approaches","volume":"25","author":"Pastena","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","volume":"112","author":"Bareche","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s11912-024-01560-3","article-title":"Recombination repair deficiency (HRD) in breast cancer: an overview of the current global landscape","volume":"26","author":"Daly","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-018-4807-x","article-title":"Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer","volume":"171","author":"Telli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"biomark Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01599-0","article-title":"Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer","volume":"126","author":"Parkes","year":"2022","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","article-title":"Recent progress in immune evasion mechanisms of triple-negative breast cancer","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study","volume":"113","author":"Emens","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcac018","article-title":"Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response","volume":"4","author":"Thompson","year":"2022","journal-title":"NAR Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response \u2013 final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234191","article-title":"Prognostic value of the residual cancer burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy","volume":"15","author":"Hamy","year":"2020","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01251-3","article-title":"Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of residual cancer burden (RCB) and Neo-Bioscore","volume":"124","author":"Laas","year":"2021","journal-title":"Br J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP inhibitors for breast cancer treatment: a review","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41523-017-0052-4","article-title":"A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity","volume":"3","author":"Litton","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2020","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad139","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study","volume":"28","author":"Litton","year":"2023","journal-title":"Oncologist"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01603-4","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status","volume":"31","author":"Telli","year":"2024","journal-title":"Breast Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01506","article-title":"Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235633","article-title":"Homologous recombination deficiency detection algorithms: a systematic review","volume":"15","author":"Mark","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405361","article-title":"Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches","volume":"14","author":"Guffanti","year":"2024","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41467-023-37537-2","article-title":"Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers","volume":"14","author":"Ter Brugge","year":"2023","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096253","article-title":"Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616872","article-title":"New dimensions of PD-1\/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives","volume":"16","author":"Tong","year":"2025","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00362-1","article-title":"Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer","volume":"8","author":"Loi","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00407","article-title":"Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention","volume":"7","author":"Saut\u00e8s-Fridman","year":"2016","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in HER2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01678-9","article-title":"Decoding the tumor microenvironment with spatial technologies","volume":"24","author":"Walsh","year":"2023","journal-title":"Nat Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","article-title":"Methods and applications for single-cell and spatial multi-omics","volume":"24","author":"Vandereyken","year":"2023","journal-title":"Nat Rev Genet"},{"key":"B88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","article-title":"Method of the year: spatially resolved transcriptomics","volume":"18","author":"Marx","year":"2021","journal-title":"Nat Methods"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00926-7","article-title":"Spatial landscapes of cancers: insights and opportunities","volume":"21","author":"Chen","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01041-y","article-title":"Breast tumor microenvironment structures are associated with genomic features and clinical outcome","volume":"54","author":"Danenberg","year":"2022","journal-title":"Nat Genet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677363","article-title":"Roles of tumor-associated macrophages in triple-negative breast cancer progression","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage biology and mechanisms of immune suppression in breast cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-0578-x","article-title":"Integrating spatial gene expression and breast tumour morphology via deep learning","volume":"4","author":"He","year":"2020","journal-title":"Nat BioMed Eng"},{"key":"B97","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1038\/s41467-023-43458-x","article-title":"High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis","volume":"14","author":"Janesick","year":"2023","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000538344","article-title":"Challenges and opportunities for the clinical translation of spatial transcriptomics technologies","volume":"4","author":"Smith","year":"2024","journal-title":"Glomerular Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Mart\u00edn","year":"2025","journal-title":"Ann Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05940-w","article-title":"PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours","volume":"617","author":"Bergholz","year":"2023","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630464","article-title":"Immunotherapy resistance in triple-negative breast cancer: molecular mechanisms, tumor microenvironment, and therapeutic implications","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0465","article-title":"Ipatasertib plus paclitaxel for patients with PIK3CA\/AKT1\/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 phase III trial","volume":"30","author":"Dent","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.12.012","article-title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","volume":"37","author":"Schmid","year":"2026","journal-title":"Ann Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz177","article-title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","volume":"30","author":"Oliveira","year":"2019","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00512-7","article-title":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","volume":"9","author":"Stecklein","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2013 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci Transl Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat Rev Genet"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat Rev Genet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707779","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics","volume":"9","author":"Iorio","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5826","article-title":"Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment","volume":"12","author":"Yin","year":"2023","journal-title":"Cancer Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7881","article-title":"MicroRNA-146a inhibits NF-\u03baB activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells","volume":"18","author":"Zhou","year":"2019","journal-title":"Exp Ther Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154132","article-title":"Non-coding RNAs, another side of immune regulation during triple-negative breast cancer","volume":"239","author":"Alghazali","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1289538","article-title":"Communication molecules (ncRNAs) mediate tumor-associated macrophage polarization and tumor progression","volume":"12","author":"Yao","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010127","article-title":"The role of miRNAs in the prognosis of triple-negative breast cancer: a systematic review and meta-analysis","volume":"13","author":"Santana","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1162463","article-title":"New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer","volume":"10","author":"Fu","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B133","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13058-025-02124-4","article-title":"Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients","volume":"27","author":"Fontana","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.010","article-title":"The role of extracellular vesicles in cancer","volume":"186","author":"Kalluri","year":"2023","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092317","article-title":"Circulating miRNAs in breast cancer diagnosis and prognosis","volume":"14","author":"Cardinali","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29020055","article-title":"Circulating exosomal microRNAs as predictive biomarkers of neoadjuvant chemotherapy response in breast cancer","volume":"29","author":"Todorova","year":"2022","journal-title":"Curr Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221884","article-title":"Circulating micro-RNAs predict the risk of recurrence in triple-negative breast cancer","volume":"13","author":"Kujala","year":"2024","journal-title":"Cells"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000004579","article-title":"Extracellular vesicle-mediated microRNA signaling: expanding insights into intercellular communication and disease modulation","volume":"88","author":"Batool","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1529907","article-title":"MicroRNAs in breast cancer-new frontiers in diagnosis, targeted therapy, and prognosis assessment","volume":"15","author":"Xiao","year":"2025","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1842762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:49:27Z","timestamp":1784695767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1842762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":139,"alternative-id":["10.3389\/fonc.2026.1842762"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1842762","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1842762"}}